Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study.
Publication/Presentation Date
5-14-2025
ISSN
1097-6787
Published In/Presented At
Eichenfield, L. F., Stein Gold, L. F., Simpson, E. L., Zaenglein, A. L., Armstrong, A. W., Tollefson, M. M., Soong, W., Lee, L. W., Devani, A. R., Forman, S. B., Siri, D. D., Kallender, H., Angel, B., Li, Q., Chen, X., & Paller, A. S. (2025). Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study. Journal of the American Academy of Dermatology, S0190-9622(25)02124-3. Advance online publication. https://doi.org/10.1016/j.jaad.2025.05.1385
Disciplines
Medicine and Health Sciences
PubMedID
40378883
Department(s)
Department of Medicine Faculty
Document Type
Article
COinS